BACKGROUND/AIMS: Eradication of Helicobacter pylori is widely accepted as initial therapy for low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma. However, approximately 20% of patients with this disease are not responsive to H. pylori eradication therapy. The aim of this study was to assess remission and relapse rates of low-grade gastric MALT lymphoma after H. pylori eradication and identify the clinical factors that affect remission. METHODS: Thirty-nine patients diagnosed with gastric MALT lymphoma (May 2003 to May 2010) were retrospectively analyzed. RESULTS: Of the 39 patients, 30 (77%) had a H. pylori infection. There were 35/39 (90%) patients with stage I. Among stage I, 25 patients with the infection underwent eradication therapy and 22/25 (88%) achieved remission. The total regression rate with eradication only in stage I was 24/28 (86%). The median time to remission was 98 days (range, 22 to 397 days). Age, tumor location, invasion depth, H. pylori burden, and severity of mononuclear leukocyte and neutrophil infiltration were not related to remission. However, patients with less neutrophil infiltration were more likely to achieve a successful first H. pylori eradication (p=0.049). CONCLUSIONS: The results show that the rate of low-grade gastric MALT lymphoma regression (86%) with H. pylori eradication alone was higher than that in Western studies (77.8%) and that neutrophil infiltration was inversely related to success of the first H. pylori eradication procedure.
BACKGROUND/AIMS: Eradication of Helicobacter pylori is widely accepted as initial therapy for low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma. However, approximately 20% of patients with this disease are not responsive to H. pylori eradication therapy. The aim of this study was to assess remission and relapse rates of low-grade gastric MALT lymphoma after H. pylori eradication and identify the clinical factors that affect remission. METHODS: Thirty-nine patients diagnosed with gastric MALT lymphoma (May 2003 to May 2010) were retrospectively analyzed. RESULTS: Of the 39 patients, 30 (77%) had a H. pyloriinfection. There were 35/39 (90%) patients with stage I. Among stage I, 25 patients with the infection underwent eradication therapy and 22/25 (88%) achieved remission. The total regression rate with eradication only in stage I was 24/28 (86%). The median time to remission was 98 days (range, 22 to 397 days). Age, tumor location, invasion depth, H. pylori burden, and severity of mononuclear leukocyte and neutrophil infiltration were not related to remission. However, patients with less neutrophil infiltration were more likely to achieve a successful first H. pylori eradication (p=0.049). CONCLUSIONS: The results show that the rate of low-grade gastric MALT lymphoma regression (86%) with H. pylori eradication alone was higher than that in Western studies (77.8%) and that neutrophil infiltration was inversely related to success of the first H. pylori eradication procedure.
Authors: S Nakamura; K Aoyagi; M Furuse; H Suekane; T Matsumoto; T Yao; Y Sakai; T Fuchigami; I Yamamoto; M Tsuneyoshi; M Fujishima Journal: Am J Pathol Date: 1998-05 Impact factor: 4.307
Authors: Thomas Wündisch; Christian Thiede; Andrea Morgner; Astrid Dempfle; Annette Günther; Hongxiang Liu; Hongtao Ye; Ming-Qing Du; Theo D Kim; Ekkehard Bayerdörffer; Manfred Stolte; Andreas Neubauer Journal: J Clin Oncol Date: 2005-10-03 Impact factor: 44.544
Authors: Eun Jeong Gong; Ji Yong Ahn; Hwoon-Yong Jung; Hyungchul Park; Young Bo Ko; Hee Kyong Na; Kee Wook Jung; Do Hoon Kim; Jeong Hoon Lee; Kee Don Choi; Ho June Song; Gin Hyug Lee; Jin-Ho Kim Journal: Gut Liver Date: 2016-09-15 Impact factor: 4.519